Selitrectinib

DB14896InvestigationalSmall molecule

Selitrectinib is under investigation in clinical trial NCT03215511 (Phase 1/2 Study of LOXO-195 in Patients With Previously Treated NTRK Fusion Cancers).

Formula / weight: C₂₀H₂₁FN₆O · 380.427 g/mol (avg)
Code names: LOXO-195

Resolves to

Compound

UNII0J45910S3XCAS2097002-61-2ChEMBLCHEMBL4297627

Structure

InChIKeyOEBIHOVSAMBXIB-SJKOYZFVSA-NSMILESC[C@@H]1CCC2=C(C=C(F)C=N2)[C@H]2CCCN2C2=NC3=C(C=NN3C=C2)C(=O)N1

Targets

P04629NTRK1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

4Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with Selitrectinib, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account